TrialSite has chronicled the potential of famotidine since nearly the start of the pandemic. No other media has tracked as many famotidine studies, from the first breakthrough reported by Dr. Robert Malone to studies at Beloit Hospital, Wisconsin to earlier investigations led by Cold Spring Harbor Laboratory and Feinstein Institutes for Medical Research at Northwell Health, New York State’s largest health system. Recently published in Gut, another study highlights the potential of famotidine.
In a study previously covered by TrialSite and now peer-reviewed and published, a New York-based study team involving both Feinstein Institutes for Medical Research and Cold Spring Harbor Laboratory contribute to further evidence showcasing the potential of famotidine as a treatment for COVID-19.
Led by Dr. Tobias Janowitz of Cold Spring Harbor Laboratory, the double-blinded and placebo-controlled clinical trial indicates oral famotidine is both safe and well tolerated. Moreover, the study team, also including Dr. Christine Brennan, leading the way for Feinstein Institutes for Medical Research, the research arm of Northwell Health, wrote that patients with mild to moderate COVID-19 symptoms, representing the great majority of cases, experience more rapid symptom resolution. The authors point out that famotidine induced earlier resolution of type-I interferon levels in COVID-19 patients.
Check out earlier research led by Robert Malone, Kevin Tomera, MD, and Joseph Kittah, MD. For a comprehensive summary, read Dr. Michael Goodkin.
Subscribe to the Trialsitenews "SARS-CoV-2" Channel
No spam - we promise
Lead Research/investigator
Tobias Janowitz MD, Ph.D. Cold Spring Harbor Laboratory
Christina M. Brennan, MD Vice President, Clinical Research at Northwell Health -Board of Trustees ACRP -Adjunct Professor at Yeshiva University
Other authors can be viewed at the source. Oral famotidine versus placebo in non-hospitalized patients with COVID-19: a randomized, double-blind, data-intense, phase 2 clinical trial | Gut (bmj.com)